Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL28322902 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13575793 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL678442 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8089096 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13933092 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL18 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL6159149 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL474012 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8433334 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL28323975 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5606 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747611-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | Vital Biosciences Inc. (CA) | 2026-05-27 | — | — | EP | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260083968-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND ACE INHIBITORS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250090602-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-03-20 | — | — | US | claimed |
| WO-2025022286-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | VITAL BIOSCIENCES INC. (CA) | 2025-01-30 | — | — | WO | claimed |
| US-20240299465-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2024-09-12 | — | — | US | claimed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20040255959-A1 | Method and compounds to decrease the incidence of atrial fibrillation (AF) in patients with left ventricular dysfunction | INSTITUT DE CARDIOLOGIE DE (CA) | 2004-12-23 | — | — | US | claimed |
| US-20040259932-A1 | Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure | BOURASSA MARTIAL G (CA) | 2004-12-23 | — | — | US | claimed |
| WO-2004091608-A1 | DECREASING THE INCIDENCE OF ATRIAL FIBRILLATION (AF) IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION WITH ACE INHIBITORS OR ANGIOTENSIN II RECEPTOR ANTAGONISTS | INSTITUT DE CARDIOLOGIE DE MONTRÉAL / MONTRÉAL HEART INSTITUTE (CA) | 2004-10-28 | — | — | WO | claimed |
| WO-2004080482-A2 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS TO PREVENT DIABETES IN A SUBJECT WITH CHRONIC HEART FAILURE | INSTITUT DE CARDIOLOGIE DE MONTRÉAL / (CA) | 2004-09-23 | — | — | WO | claimed |
| WO-2003106698-A1 | METHOD AND SYSTEM FOR DISCLOSING MECHANISM-BASED ENZYME INHIBITORS | THOMSEN BIOSCIENCE A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| JP-2003508349-A | — | — | 2003-03-04 | — | — | JP | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| EP-1183011-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | Esperion Mergerco, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2000069412-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEVELOPMENT, INC. (US) | 2000-11-23 | — | — | WO | claimed |